Evaluation of the potential for and clinical impact of increased ALT in patients using the AbbVie 2-DAA or 3-DAA Regimens in a real world setting

First published 06/07/2016

Last updated 02/07/2024

EU PAS number:

EUPAS13832

Study

Finalised

Documents

Study protocol

Initial protocol

p15421-protocol-pmos-abstract

English (57.75 KB - PDF) View document

Updated protocol

p15421-protocol-pmos FINAL_Redacted

First published: 22/02/2024

English (200.83 KB - PDF) View document

Study results

p15421-pmos-results-abstract-final-redacted

English (1.62 MB - PDF) View document

Study report

Other information

Secondary tabs